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Objective To investigate the safety, efficacy, and pharmacokinetic profile of dexmedetomidine in preterm and
full-term neonates $28 to #44 weeks gestational age.
Study design Forty-two intubated, mechanically ventilated patients (n = 42) were grouped by gestational age into
group I (n = 18), $28 to <36 weeks, and group II (n = 24), $36 to #44 weeks. Within each age group, there were 3
escalating dose levels, including a loading dose (LD, mg/kg) followed by a maintenance dose (MD, mg$kg1$h1) for
6-24 hours: level 1, 0.05 LD/MD; level 2, 0.1 LD/MD; and level 3, 0.2 LD/MD. The primary endpoint was the number
of patients requiring sedation as determined by the Neonatal Pain, Agitation, Sedation Scale.
Results During dexmedetomidine infusion, 5% of Neonatal Pain, Agitation, Sedation Scale scores were >3,
indicatingagitation/pain,with4patients (10%) requiringmoresedationand17 (40%) requiringmoreanalgesia.Though
there was significant variability in pharmacokinetic variables, group I appeared to have lower weight-adjusted plasma
clearance (0.3 vs 0.9 L$h1$kg1) and increased elimination half-life (7.6 vs 3.2 hours) comparedwith group II. Fifty-six
adverse events (AEs) were reported in 26 patients (62%); only 3 AEs (5%) were related to dexmedetomidine. There
were no serious AEs and no AEs or hemodynamic changes requiring dexmedetomidine discontinuation.
Conclusion Dexmedetomidine is effective for sedating preterm and full-term neonates and is well-tolerated
without significant AEs. Preterm neonates had decreased plasma clearance and longer elimination half-life.
(J Pediatr 2014;164:276-82).
P
roviding adequate sedation and analgesia for neonatal patients with the least amount of side effects is an important
component of care in the intensive care unit. Current neonatal drug regimens used to achieve these goals generally
consist of combinations of benzodiazepines and opioids. However, these drugs have been associated with significant
side effects, including tolerance, physical dependency, paradoxical agitation, withdrawal, inconsistent sedation, and respiratory
depression.1,2 Moreover, recent studies have demonstrated that benzodiazepines and opioids can cause neuroapoptosis and
neurodevelopmental abnormalities in neonatal animals.3,4 In some preliminary animal studies, dexmedetomidine has shown
potential neuroprotective properties, including prevention of neuroapoptosis induced by other agents.5,6From the 1Department of Pediatric Critical Care
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AE Adverse event
AUC Area under the concentration curve
BP Blood pressure
CLW Plasma clearance
HR Heart rate
LD Loading dose
MD Maintenance dose
N-PASS Neonatal Pain, Agitation, Sedation Scale
PK Pharmacokinetic
t1/2 Half-life
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Vol. 164, No. 2  February 2014are similar in pediatric patients and adults.15-18 However, a
pooled analysis of 4 studies found increasing plasma clearance
(CLw) of dexmedetomidine with age, indicating that
age-specific dosing regimens may be required.19 Neonatal PK
data for dexmedetomidine are lacking, and in general there
are important PK differences between preterm and term
neonates that may affect and complicate drug therapy.
The objective of this phase II/III, open-label study was to
characterize the safety, efficacy, and PK of dexmedetomidine
in preterm and term neonates $28 to #44 weeks gestational
age.
Methods
This was a phase II/III, open-label, multicenter safety, efficacy
and PK trial in preterm and term neonates. Eleven centers
from North America (Children’s Hospital of Pittsburgh, 13
patients; RubyMemorial Hospital, 7 patients; Duke Children’s
Hospital, 5 patients; Greenville Hospital System, 3 patients;
Kosair Children’s Hospital, 3 patients; Loyola University Med-
icalCenter, 2 patients;WesleyMedicalCentre, 2 patients; Akron
Children’s Hospital Medical Center, 1 patient; Georgia Health
Sciences University, 1 patient; Children’s Hospital of Los
Angeles, 1 patient; Medical University of South Carolina, 1
patient) and 1 center from Central America (Hospital Roose-
velt, Guatemala City, 3 patients) were used and received
approval by their respective Institutional Review Boards and/
or Ethics Committees. Written informed consent was obtained
from the parent/legal guardian of each patient before any study-
related activity.The studywas conducted in accordancewith the
International Conference on Harmonization guidelines.
The study population consisted of initially intubated and
mechanically ventilated neonates, gestational age$28 to#44
weeks, anticipated to require a minimum of 6 hours of contin-
uous intravenous sedation in an intensive care setting. Patients
in the following age ranges were enrolled: preterm neonates
$28 to <36 weeks gestational age (group I) and term neonates
born at$36 to#44 weeks gestational age (group II).
Exclusion criteria included weight <1 kg; heart rate (HR)
<120 bpm; second- or third-degree heart block (unless a
pacemaker was in place); neurologic conditions prohibiting
accurate evaluation of sedation, such as catastrophic brain
injury (patients who survive extensive brain damage but
with residual severe neurologic impairment), or other severe
mental disorders that would make the response to sedatives
unpredictable and/or assessment of the Neonatal Pain, Agita-
tion, Sedation Scale (N-PASS) unreliable; immobility from
neuromuscular disease or continuous infusion of a neuro-
muscular blocking agent; exposure to any investigational
drug within 30 days before dexmedetomidine administra-
tion; previous exposure to dexmedetomidine as part of an
investigational study; and allergies to or contraindications
for fentanyl, morphine, midazolam, or dexmedetomidine.
In addition, because dexmedetomidine CLw decreases with
increasing severity of hepatic impairment, an alanine amino-
transferase level >115 U/L (ie, 2-2.5 times the upper limit of
normal) was used to exclude patients.Patients were assigned to either age group I ($28 to <36
weeks) or age group II ($36 to #44 weeks) according to
the gestational age at birth as determined by the date of the
mother’s last menstrual period plus the weeks after birth to
the day of enrollment. The patients in each group were
then sequentially assigned to 1 of 3 escalating dose levels
(Figure 1; available at www.jpeds.com): level 1: loading
dose (LD), 0.05 mg/kg; maintenance dose (MD), 0.05 mg/
kg/h; level 2: LD, 0.1 mg/kg; MD, 0.1 mg/kg/h; level 3: LD,
0.2 mg/kg; MD, 0.2 mg/kg/h. Although each age group
could enroll simultaneously, enrollment of each group in
the next dose level could not begin until all patients had
completed the previous dose level and a Data Safety and
Monitoring Board, consisting of 2 independent physicians
and a biostatistician, approved the dose escalation.
In the absence of data on dexmedetomidine use in preterm
neonates and with only limited data on use in term neonates,
we adopted a cautious study design, using a stepwise dose
escalation and lower doses of dexmedetomidine than those
typically used in older children and adults. This approach
was expected to reduce the risk of bradycardia and hypoten-
sion, potential sympatholytic side effects of dexmedetomi-
dine.
The study drug, dexmedetomidine hydrochloride (100 mg/
mL base), was administered via a controlled infusion device.
Patients were first given an LD over 10-20 minutes, followed
by continuous infusion of an MD for 6-24 hours (Figure 1).
The need for more sedation or analgesia was determined by
the clinical team and based on assessment of N-PASS values.20
The N-PASS tool, which has been validated in both preterm
and term neonates, uses 5 assessment criteria (crying/irritabil-
ity, behavior/state, facial expression, extremities/tone, and vital
signs), assigning a score ranging from2 (well sedated) to +2
(experiencing pain/agitation) for each variable, to determine
the effectiveness of sedation and analgesia. For each patient,
the N-PASS was evaluated throughout the LD andMDperiods
according to the schedule shown inFigure1. Significant pain or
agitation was considered at an N-PASS score of >3, at which
point supplemental therapy (sedation or analgesia) was
indicated; sedation or analgesia also could be administered at
the discretion of the investigator. Midazolam (0.05-0.15
mg$kg1$dose1) was administered for the supplemental
sedation, and fentanyl (0.5-2 mg/kg bolus or 1-2 mg$kg1$h1
continuous infusion) or morphine (0.025-0.1 mg/kg bolus or
0.01-0.02 mg$kg1$h1 continuous infusion) was used if
more analgesia was required.1,21
All medications given within 24 hours before the start of
dexmedetomidine, as well as concomitant and postinfusion
medications, were recorded. The following medications
were prohibited during dexmedetomidine infusion: sedatives
and analgesics other than dexmedetomidine, midazolam,
fentanyl, and morphine; continuous infusion or repeated
dosing of any neuromuscular blocking agent that would
preclude accurate assessment of N-PASS measurements;
alpha-2 agonists/antagonists other than dexmedetomidine;
and anesthetics or analgesics administered via the epidural
or spinal route.277
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The primary efficacy endpoint was the number of patients
requiring midazolam for sedation during dexmedetomidine
administration. Secondary endpoints included the use of
medications (fentanyl or morphine) for analgesia; changes
from baseline in vital signs (HR, blood pressure [BP], respi-
ratory rate), and oxygen saturation; time spent with a total
N-PASS score >3; and time to extubation from dexmedeto-
midine initiation.
PK Analysis
ForPK analysis, 8 blood samples (0.15mL each)were collected
via arterial, venous, or capillary sampling intoheparinized vac-
uum tubes (Figure 1). Dexmedetomidine was extracted from
plasma using an automated protein extraction procedure and
analyzed by high-performance liquid chromatography with
tandem mass spectroscopy detection. The calibration curve
range was 29.9 to 2994 pg/mL. Between-run accuracy for the
method was 100.8%-103.9% of theoretical quality control
concentrations, and between-precision of theoretical quality
control concentrations was 3.7%-8.4%.
Descriptive statistics were used to summarize PK variables,
including total exposure (area under the concentration curve
[AUC]), maximal concentration, elimination t1/2, weight-
adjusted volume of distribution, weight-adjusted volume of
distribution at steady state, and weight-adjusted CLw, for
each dose level and age group. Noncompartmental methods
were used to estimate these standard PK variables.
Safety Evaluation
Safety evaluation included temperature, vital signs, 12-lead
electrocardiogram, laboratory measurements including com-
plete blood count and chemistry, liver function/injury, fluid
input-output balance, adverse events (AEs), and treatment-
emergent AEs. The individual site principal investigators
were responsible for classifying the AEs according to severity
asmild (transient and easily tolerated by the patient),moderate
(causes discomfort and interrupts patient’s usual activities), or
severe (causes considerable interference with patient’s usual
activities and may be incapacitating or life-threatening) and
according to their relationship with dexmedetomidine
(ie, definitely related, probably related, possibly related, prob-
ably not related, or not related).
Statistical Analyses
Determination of sample size was based on a pairwise com-
parison between the low-dose group and the high-dose
group. It was expected that 90% of subjects in the low-dose
group and 45% of subjects in the high-dose group would
require additional sedation. Thus, with 14 subjects in each
group, there would be 72% power to detect the difference,
assuming a 1-sided test for 2 proportions with a = 0.05.
Because of administrative considerations, the study was
completed in 2 phases, with an initial enrollment of 36
patients and subsequent enrollment of the final 6 patients in
group I, dose level 3. Owing to the difficulties encountered
with blood sampling in very small neonates, for the latter final2786 preterm patients, PK samples were not drawn. For efficacy,
safety, and PK data, descriptive statistics are presented as
counts (%) for categorical variables andmean SDormedian
(range) for continuous variables. For comparison of the per-
centage of patients with previous midazolam or fentanyl/
morphine use vs those requiring midazolam or fentanyl/
morphine during the dexmedetomidine administration, the
FREQ procedure was used, followed by the Fisher exact test.
Albumin and bilirubin levels were compared in the 2 groups
using the Student t test, and PK variables were compared using
the nonparametric Mann-Whitney U test. Statistical analyses
were performed with SAS version 9.1 (SAS Institute, Cary,
North Carolina). Graphs were created in SigmaPlot version
10.0 (Systat Software, San Jose, California).
Results
The 42 patients enrolled in the study included 18 in group I and
24 in group II (Figure 2; available at www.jpeds.com). All
patients completed the treatment. Most of the patients in the
lowest dose level (level 1) were not included in the PK
analysis because drug levels were below the limit of detection
(Figure 2). The patients included in the PK-evaluable
population included 4 of 14 (28.6%) from dose level 1, 11 of
14 (78.6%) from dose level 2, and 7 of 8 (87.5%) from dose
level 3, suggesting that the exclusions were dose- dependent.
Demographic data are presented in Table I. Six patients
(14%) were enrolled after cardiopulmonary bypass, and 12
patients (29%) were enrolled after surgery.
Efficacy
Primary Endpoint. Additional sedation was administered
in only 10% of the study population. Patients in group I
required no extra sedation, and 4 patients in group II
(17%) were given midazolam (Table II). The mean doses
of midazolam were 0.10 mg/kg for dexmedetomidine dose
level 1 (n = 1), 0.15 mg/kg for dose level 2 (n = 1), and
0.32  0.41 mg/kg for dose level 3 (n = 2), with a total
mean dose of 0.22  0.26 mg/kg.Secondary Endpoints. Additional analgesia was adminis-
tered to 17 patients (40%) (Table II). Fentanyl was given in 3
patients in group I (17%). In group II, 9 patients received
only fentanyl (37%), 2 received fentanyl and morphine
(8%), and 3 received only morphine (12%).
N-PASS scores were collected at a total of 723 time points
throughout dexmedetomidine infusion across all age groups
and dose levels. Five percent of these N-PASS scores were >3
at any time point, 77% were between 5 and +3, and 18%
were between 6 and 10, indicating a deeper level of seda-
tion. In general, patients at all dose levels had a total N-PASS
score of >3 for only a short time, indicating that most did not
manifest signs of pain or agitation (Table II).
Across all age groups and dose levels, a total of 8 patients
(20%) were extubated, at a median of 4.3 hours (range,
0.17-21 hours) after dexmedetomidine initiation.Chrysostomou et al
Table I. Patient demographics*
Group I† Group II† Total
Level 1
(n = 6)
Level 2
(n = 6)
Level 3
(n = 6)
Total
(n = 18)
Level 1
(n = 8)
Level 2
(n = 8)
Level 3
(n = 8)
Total
(n = 24)
Level 1
(n = 14)
Level 2
(n = 14)
Level 3
(n = 14)
Total
(n = 42)
Gestational age at birth,
wk, mean (SD)
30.0 (1.6) 32.5 (2.4) 32.5 (2.7) 31.8 (2.4) 38.0 (2.1) 38.9 (2.2) 39.1 (1.6) 38.7 (2.0) 34.7 (4.4) 36.1 (3.9) 36.3 (3.9) 35.7 (4.0)
Age at screening, wk,
mean (SD)z
1.00 (0.7) 0.38 (0.2) 0.8 (1.4) 0.78 (0.9) 2.12 (2.3) 1.64 (1.2) 2.23 (1.6) 1.99 (1.7) 1.64 (1.8) 1.10 (1.1) 1.7 (2.0) 1.48 (1.5)
Sex, female, n (%) 4 (67) 3 (50) 4 (67) 11 (61) 2 (25) 3 (37) 0 5 (21) 6 (43) 6 (43) 4 (29) 16 (38)
Race, n (%)
Caucasian 3 (50) 2 (33) 5 (83) 10 (56) 7 (87) 8 (100) 6 (75) 21 (87) 10 (71) 10 (71) 11 (79) 31 (74)
Black 0 1 (17) 0 1 (6) 0 0 0 0 0 1 (7) 0 1 (2)
Other 3 (50) 3 (50) 1 (17) 7 (39) 1 (13) 0 2 (25) 3 (13) 4 (29) 3 (21) 3 (21) 10 (24)
Weight, kg, mean (SD) 1.4 (0.3) 1.7 (0.4) 1.9 (0.8) 1.7 (0.6) 3.4 (0.5) 3.0 (0.5) 3.4 (0.6) 3.3 (0.6) 2.6 (1.1) 2.4 (0.8) 2.7 (1.0) 2.6 (1.0)
CPB, n (%) 0 0 0 0 4 (50) 1 (12) 1 (12) 6 (25) 4 (29) 1 (7) 1 (7) 6 (14)
Surgery, n (%) 0 0 1 (17) 1 (6) 3 (37) 2 (25) 6 (75) 11 (46) 3 (21) 2 (14) 7 (50) 12 (29)
CPB, cardiopulmonary bypass.
*Intent-to-treat, efficacy evaluable, and safety evaluable populations are equivalent.
†Age group I included preterm neonates ages $28 to <36 weeks gestational age, and age group II included term neonates ages $36 to <44 weeks gestational age.
zAll patients were administered the study drug within 3 days of screening, and 90% within 24 hours.
February 2014 ORIGINAL ARTICLESFigure 3 (available at www.jpeds.com) shows the trends in
mean cardiovascular and respiratory variables during
dexmedetomidine infusion and for the first 6 hours after
dexmedetomidine discontinuation. Comparison of baseline
hemodynamic values with the lowest values measured
during dexmedetomidine infusion showed that HR
decreased by an average of 12%  9% at 7.7  7.3 hours,
and systolic BP decreased by 14%  12% at 6.5  7 hours.
Overall, there were no significant hemodynamic differences
among the dose regimens.
Thirteen patients (31%) received midazolam, at a median of
4 hours (range, 0.5-22hours) before starting dexmedetomidine,
and 20 patients (48%) received either fentanyl ormorphine at a
median of 1.4 hours (range, 0-10 hours) before starting dexme-
detomidine. Previous use of midazolam was tabulated against
the primary efficacy endpoint, that is, the proportion of patients
who receivedmidazolamduringdexmedetomidine administra-
tion.Midazolamwas administered to7%of thepatientswithnoTable II. Summary of efficacy data
Dose level 1
(n = 14)
Primary efficacy
Patients with rescue sedation, n (%)*
Group I† 0
Group II† 1 (12)
Total 1 (7)
Amount of midazolam in age group II, mg/kg (n) 0.10 (1)
Secondary efficacy
Patients with rescue analgesia, n (%)z
Group I† 1 (17)
Group II† 4 (50)
Total 5 (36)
Time spent with N-PASS >3, h median (range)x
Group I† 0.5 (0-1.0)
Group II† 0 (0-1.0)
Total 0 (0-1.0)
*Rescue sedation was achieved with midazolam.
†Age group I included preterm neonates $28 to <36 weeks gestational age, and age group II inclu
zRescue analgesia was achieved with either fentanyl or morphine. Fentanyl was given in 3 (17%) pati
morphine, and 3 (12%) received only morphine.
xN-PASS scores were collected at 723 time points during dexmedetomidine infusion; 5% of these
A Phase II/III, Multicenter, Safety, Efficacy, and Pharmacokinetic
and Term Neonatesprevious exposure to midazolam and to 15% of those patients
with previousmidazolam exposure (P= .62). In addition, given
the sedative effect of opioids, previous use of fentanyl and/or
morphine was also tabulated against the primary endpoint.
Nopatientswithout previous exposure to these opioids received
midazolam, but 15% of patients with previous exposure to
opioids received midazolam (P = .44).
PK
PK variables are summarized inTable III. Overall, the patients
in group I appeared to have lower CLw (0.3 vs 0.9 L$h
1$kg1),
increased elimination t1/2 (7.6 vs 3.2 hours), and increased
AUC0-N dose (2049 vs 357 pg$mL
1$h$mg1) compared
with those in group II.
Safety
All patients completedaminimumof6hoursofdexmedetomi-
dine infusion, with the majority of patients in both age groupsDose level 2
(n = 14)
Dose level 3
(n = 14)
Total
(n = 42)
0 0 0
1 (12) 2 (25) 4 (17)
1 (7) 2 (14) 4 (10)
0.15 (1) 0.32  0.41 (2) 0.22  0.26 (4)
1 (17) 1 (17) 3 (17)
4 (50) 6 (75) 14 (58)
5 (36) 7 (50) 17 (40)
0 (0) 0 (0-1.9) 0 (0-1.9)
0.1 (0-5.0) 0.3 (0-2.0) 0.1 (0-5.0)
0 (0-5.0) 0.2 (0-2.0) 0.0 (0-5.0)
ded term neonates $36 to <44 weeks gestational age.
ents in group I and 9 (37%) patients in group II; in group II, 2 patients (8%) received fentanyl and
723 scores were >3, 77% were between 5 and +3, and 18% were between 6 and 10.
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Table III. Summary of PK variables
CLw,
L$hr1$kg1
AUC0-t,
pg$mL1$h
AUC0-N,
pg$mL1$h
AUC0-N dose,
pg$mL1$h$mg1
Cmax,
pg/mL
Vdw,
L/kg
Vssw,
L/kg
t1/2,
h
Group I
Level 1
1 0.41 69 854 2049 140 1.79 2.74 3.02
2 NA 1313 NA NA 102 NA NA NA
3 NA 384 NA NA 74 NA NA NA
Level 2
4 NA 142 NA NA 34 NA NA NA
5 NA 508 NA NA 123 NA NA NA
6 0.19 8421 11 485 2827 505 2.11 2.45 7.61
7 0.43 1012 1614 1564 116 5.70 5.89 9.11
8 NA 448 NA NA 74 NA NA NA
9 NA 459 NA NA 83 NA NA NA
Total 0.3
(0.2-0.4)
508
(142-8421)
1614
(853-11 485)
2049
(1564-2827)
102
(34-505)
2.1
(1.8-5.7)
2.7
(2.5-5.9)
7.6
(3.0-9.1)
Group II
Level 1
10* 0.61 432 571 452 78 2.83 2.21 3.19
Level 2
11* NA 261 NA NA 56 NA NA NA
12 1.21 406 580 272 76 4.37 3.10 2.10
13 0.97 508 725 338 67 5.33 4.64 3.93
14 0.62 702 1161 653 99 8.37 8.49 9.40
15 0.24 9428 9781 1261 965 1.98 0.54 5.73
Level 3
16* 0.30 4369 4694 958 1019 1.30 0.47 3.03
17 0.92 2130 3189 377 192 10.99 10.91 8.24
18 0.17 7828 8030 2494 1394 0.81 0.10 3.21
19 1.40 3388 3571 227 163 6.92 5.23 3.42
20 1.03 3618 3710 255 196 2.14 1.43 1.43
21 1.47 3231 2249 192 227 2.18 9.22 1.03
22 1.06 3255 3400 270 197 4.30 4.66 2.81
Total 0.9
(0.2-1.5)
3231
(261-9428)
3295
(571-9781)
357
(192-2494)
192
(56-1394)
3.6
(0.8-11.0)
3.9
(0.1-10.9)
3.2
(1.0-9.4)
P value, group I vs group II† .14 .16 .94 .02 .19 .63 .94 .36
AUC0-N, area under the concentration -time curve, from 0 hours to infinity; AUC0-N dose, area under the concentration -time curve, from 0 hours to infinity; AUC0-t, area under the concentration-time
curve, from 0 hours to final time of positive detection; Cmax, maximal concentration; NA, not available (insufficient data to calculate the parameter); Vdw, weight-adjusted volume of distribution; Vssw,
weight-adjusted volume of distribution at steady state.
*CPB patient.
†Mann-Whitney U test.
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The safety profile for dexmedetomidine in neonates was typical
of the critically ill, high-risk neonatal population and
postoperative neonatal surgical patients. AEs were reported
in a total of 26 patients (62%), including 11 (61%) in group I
and 15 (62.5%) in group II. Among these, 3 patients (7%)
reported a total of 4 AEs related to dexmedetomidine. Three
AEs were assessed as definitely related to dexmedetomidine:
diastolic hypotension in group I, dose level 2; hypertension
in group II, dose level 1; and significant agitation in group II,
dose level 3. One AE was assessed as possibly related to
dexmedetomidine: mild, respiratory acidosis in group I, dose
level 2. There were no serious AEs related to
dexmedetomidine and no AEs that led to discontinuation of
dexmedetomidine. No significant laboratory or
electrocardiographic measurement changed during the study.
Discussion
Since the initial Food and Drug Administration approval of
dexmedetomidine for the sedation of initially intubated
and mechanically ventilated adults in 1999, this drug has280been investigated in numerous off-label pediatric studies,
most of which demonstrated a rather favorable safety and
efficacy profile.2,8-10,12-17,19,22,23 Studies describing its use in
neonates are scarce and mostly retrospective in nature, how-
ever, and there no reports on the use of dexmedetomidine in
preterm neonates.24 The present study provides pivotal
multicenter efficacy, safety, and PK data on dexmedetomi-
dine use in term and preterm neonates. We found that the
majority of patients were adequately sedated, with only 9%
requiring extra sedation. We also found that 60% of the
patients did not require additional analgesia.
Dexmedetomidine, with its 1600:1 a2:a1 adrenoreceptor
specificity, is considered a full a2 agonist, and activation of
these receptors in the locus ceruleous results in sedation and
anxiolysis.25-27 Dexmedetomidine also exerts dose-dependent
moderate primary analgesic effects through activation of a2
adrenoreceptors in the dorsal spinal horn and a subsequent
decrease in substance P release.28
Previous retrospective reports in neonates and infants have
demonstrated that dexmedetomidine can be used alone or in
conjunction with other agents to provide adequate sedation
and analgesia. In an 80-patient study that included 14 neonatesChrysostomou et al
Table IV. Summary of dexmedetomidine exposure and
AEs
Group I
(n = 18)*
Group II
(n = 24)*
Total
(n = 42)
Exposure duration, h, median
(range)
6.6 (6.0-24.0) 6.0 (6.0-14.4) 6.0 (6.0-24.0)
Patients with AEs, n (%) 11 (61) 15 (63) 26 (62)
Total AEs, n† 27 29 56
Significant agitation, n (%) 1 (4) 5 (17) 6 (11)
Hypokalemia, n (%) 1 (4) 4 (14) 5 (9)
Hypoalbuminemia, n (%) 3 (11) 0 3 (5)
Atelectasis, n (%) 0 2 (7) 2 (4)
Pleural effusion, n (%) 0 2 (7) 2 (4)
Hypocalcemia, n (%) 1 (4) 1 (3) 2 (4)
Diastolic hypotension, n (%) 1 (4) - 1 (2)
Hypertension, n (%) - 1 (3) 1 (2)
Respiratory acidosis, n (%) 1 (4) - 1 (2)
AEs related to
dexmedetomidine, n (%)z
1 (4) 2 (7) 3 (5)
Albumin level, g/dL, mean
(SD)x
2.4 (0.4) 3.1 (0.8) -
Bilirubin level, mg/dL, mean
(SD){
6.1 (2.5) 5.1 (4.2) -
*Group I: preterm neonates $28 to <36 weeks gestational age, and Group II: term neonates
$36 to <44 weeks gestational age.
†For each specific AE, the number and percent listed are based on the total number of AEs
rather than the total number of patients.
zIn addition to the 3 AEs listed, 1 AE (age group I, dose level 2) was assessed as possibly relating
to dexmedetomidine.
xSignificant difference between age groups (P = .005, Student t test).
{No significant difference between groups (P = .68).
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analgesia were documented in 94% and 90% of cases, respec-
tively.13 The dexmedetomidine dose was 0.47  0.21
mg$kg1$h1 in neonates and 0.69 0.25 mg$kg1$h1 in in-
fants (P = .003), with 25% of the patients requiring only dex-
medetomidine and 47% requiring approximately 2.6 extra
sedation/analgesic doses per 24 hours of dexmedetomidine
use. These previous results support our present findings, with
younger patients requiring lower dexmedetomidine doses.
Most dexmedetomidine AEs are related to the drug’s sym-
patholytic and or parasympathomimetic profile and appear
to be predictable and dose-dependent. In a previous study
reported by Chrysostomou et al,13 34% of the patients had
at least 1 episode of hypotension and 12% had at least 1
episode of bradycardia, and no respiratory AEs. In the
present study, we noted no significant hemodynamic or res-
piratory changes that necessitated intervention or discontin-
uation of dexmedetomidine. HR and BP decreased by
approximately 12%-14%, there were no respiratory AEs,
and 20% of patients could be extubated while receiving
dexmedetomidine.
ThePKvariables for group I appear tobedifferent than those
for the older group II patients and also different than those re-
ported previously in children and adults.15,17,21,29 The median
weight-adjusted CLW was 0.3 L$h
1$kg1, with values re-
ported in toddlers and older children ranging from 0.57-1.0
L$h1$kg1 and those reported in adults ranging from 0.47
to 0.68 L$h1$kg1. The volumeof distributionwas also signif-
icantly different, with 2.7 L/kg for group I and 3.9 L/kg for
group II. Volumes of distribution in older children and adults
reportedly range from 0.8 to 1.4 L/kg. The elimination t1/2 wasA Phase II/III, Multicenter, Safety, Efficacy, and Pharmacokinetic
and Term Neonatesalso longer, at 7.6 hours in group I and 3.2 hours in group II,
compared with 1.8-3 hours in older children and adults.
Dexmedetomidine is metabolized extensively by the liver
(phase II drug-metabolizing enzymes) to inactive metabolites
through direct N–glucuronidation, aliphatic hydroxylation
(via the cytochrome P450, 2A6 pathway), and N–methyl-
ation.7 These metabolites are eliminated in the urine (95%)
and feces (4%).5 In addition, dexmedetomidine exhibits
94% protein binding to serum albumin and a1-glycopro-
tein.7 The bound fraction is decreased significantly in
patients with hepatic dysfunction, possibly necessitating a
dose reduction. Mean CLw values in adult patients with
mild, moderate, and severe hepatic impairment are report-
edly 74%, 64%, and 53%, respectively, of those in normal
healthy patients.7 In addition, there are significant differences
between patients with severe hepatic failure and healthy adult
volunteers in the volume of distribution at steady state (3.2
0.32 L/kg vs 2.18  0.22 L/kg) and elimination t1/2 (7.51 
1.80 hours vs 2.59  0.39 hours).30
Although none of our patients had liver failure, immature
hepatic drug-metabolizing capacity, particularly of the glu-
curonidation pathway, likely played a major role, given that
many of the patients were preterm.31 Immature glucuronida-
tion, in addition to the lower protein and albumin levels nor-
mally seen in preterm neonates, allow for increased free,
unbound dexmedetomidine. Because more than 90% of dex-
medetomidine is albumin-bound, the presence of a lower
albumin level (which was found in preterm neonates), along
with the larger volume of distribution, can lead to a signifi-
cantly increased t1/2 and increased AUC values. Furthermore,
preterm neonates exhibit decreased renal glomerular filtra-
tion compared with term neonates.32 Although dexmedeto-
midine dose adjustment usually is not necessary in renal
failure, when a significant amount of dexmedetomidine is
free owing to lack of metabolism or lack of binding with
albumin, any degree of renal insufficiency would lead to an
increased t1/2 and AUC values.
Overall, preterm neonates and, to a lesser extent, term
neonates had larger volume of distribution, increased free
unbound dexmedetomidine, decreased CLw, increased t1/2,
and significantly increasedAUCvalues. In addition, the imma-
turity of the blood-brain barrier in this population32may facil-
itate the sedating properties of dexmedetomidine because of its
high lipid solubility and potentially higher cerebrospinal fluid
concentrations. All of these factors can lead not only to
increased sedative and analgesic effects of dexmedetomidine,
but also to increased side effects; thus, lower doses than those
recommended for older children and adults should be carefully
considered at initiation of dexmedetomidine.
This study was powered to evaluate efficacy, and thus any
results related to safety, including cardiorespiratory changes,
should be carefully considered. In addition, several patients
from group I had undetectable dexmedetomidine levels;
thus, PK results could be biased, because these patients
were not included in the analysis.
In conclusion, in our study cohort, dexmedetomidine was
effective in sedating critically ill, initially intubated, andStudy of Dexmedetomidine in Preterm 281
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 164, No. 2mechanically ventilated preterm and term neonates and was
well tolerated. The PK profile of dexmedetomidine appears
to be different in neonates compared with older children and
adults, exhibiting a longer t1/2 and a larger AUC, indicating
that lower doses may be required to achieve the same level of
sedation and to avoid adverse effects. n
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Figure 1. Schematic of the study design. *N-PASSmeasurements were taken before LD; at 5, 10, 15, and 20 minutes during the
LD; at the start ofMD, every 15minutes for the first hour, every 30minutes for 2 hours, and then hourly for the remainder of theMD
on dexmedetomidine discontinuation and then every 15 minutes for 1 hour, every 30 minutes for the next 2 hours, every hour for
the next 3 hours, and then every 4 hours until the last PK sample was obtained; and immediately before andwithin 5minutes after
administration of rescue midazolam, fentanyl, or morphine and within 5 minutes of every PK sample. xSamples for PK analysis
were collected as follows: at the end of the LD, at 4-8 hours of the MD for patients$2 kg, at 10-14 hours of the MD (except group
II), at the end ofMD, at 10-30minutes post-MD, at 1-2 hours post-MD for patients$2 kg, at 3-4 hours post-MD for patients <2 kg,
and at 6-10 hours post-MD.
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Figure 2. Patient disposition and analysis populations. xIn both group I and group II, most of the patients in the lowest dose level
(level 1) were not included in the PK analysis, because drug levels were below the limit of detection. EE, efficacy evaluable; ITT,
intention to treat; SE, safety evaluable.
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Figure 3. Changes in HR and systolic BP by age group and dexmedetomidine dose level. A, Average HR and B, systolic BP
plotted as functions of time relative to dexmedetomidine administration for groups I and II at all dose levels. The gap after 24
hours indicates the start of the postinfusion period.
February 2014 ORIGINAL ARTICLES
A Phase II/III, Multicenter, Safety, Efficacy, and Pharmacokinetic Study of Dexmedetomidine in Preterm
and Term Neonates
282.e3
